2itq: Difference between revisions

From Proteopedia
Jump to navigation Jump to search
No edit summary
No edit summary
Line 4: Line 4:


==Overview==
==Overview==
Mutations in the EGFR kinase are a cause of non-small-cell lung cancer. To, understand their mechanism of activation and effects on drug binding, we, studied the kinetics of the L858R and G719S mutants and determined their, crystal structures with inhibitors including gefitinib, AEE788, and a, staurosporine. We find that the mutations activate the kinase by, disrupting autoinhibitory interactions, and that they accelerate catalysis, as much as 50-fold in vitro. Structures of inhibitors in complex with both, wild-type and mutant kinases reveal similar binding modes for gefitinib, and AEE788, but a marked rotation of the staurosporine in the G719S, mutant. Strikingly, direct binding measurements show that gefitinib binds, 20-fold more tightly to the L858R mutant than to the wild-type enzyme.
Mutations in the EGFR kinase are a cause of non-small-cell lung cancer. To understand their mechanism of activation and effects on drug binding, we studied the kinetics of the L858R and G719S mutants and determined their crystal structures with inhibitors including gefitinib, AEE788, and a staurosporine. We find that the mutations activate the kinase by disrupting autoinhibitory interactions, and that they accelerate catalysis as much as 50-fold in vitro. Structures of inhibitors in complex with both wild-type and mutant kinases reveal similar binding modes for gefitinib and AEE788, but a marked rotation of the staurosporine in the G719S mutant. Strikingly, direct binding measurements show that gefitinib binds 20-fold more tightly to the L858R mutant than to the wild-type enzyme.


==Disease==
==Disease==
Line 17: Line 17:
[[Category: Receptor protein-tyrosine kinase]]
[[Category: Receptor protein-tyrosine kinase]]
[[Category: Single protein]]
[[Category: Single protein]]
[[Category: Boggon, T.J.]]
[[Category: Boggon, T J.]]
[[Category: Eck, M.J.]]
[[Category: Eck, M J.]]
[[Category: Greulich, H.]]
[[Category: Greulich, H.]]
[[Category: Li, Y.]]
[[Category: Li, Y.]]
[[Category: Meyerson, M.]]
[[Category: Meyerson, M.]]
[[Category: Woo, S.]]
[[Category: Woo, S.]]
[[Category: Yun, C.H.]]
[[Category: Yun, C H.]]
[[Category: STU]]
[[Category: STU]]
[[Category: afn941]]
[[Category: afn941]]
Line 45: Line 45:
[[Category: tyrosine-protein kinase]]
[[Category: tyrosine-protein kinase]]


''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun Feb 3 10:38:04 2008''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 17:55:56 2008''

Revision as of 18:55, 21 February 2008

File:2itq.jpg


2itq, resolution 2.68Å

Drag the structure with the mouse to rotate

CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AFN941

OverviewOverview

Mutations in the EGFR kinase are a cause of non-small-cell lung cancer. To understand their mechanism of activation and effects on drug binding, we studied the kinetics of the L858R and G719S mutants and determined their crystal structures with inhibitors including gefitinib, AEE788, and a staurosporine. We find that the mutations activate the kinase by disrupting autoinhibitory interactions, and that they accelerate catalysis as much as 50-fold in vitro. Structures of inhibitors in complex with both wild-type and mutant kinases reveal similar binding modes for gefitinib and AEE788, but a marked rotation of the staurosporine in the G719S mutant. Strikingly, direct binding measurements show that gefitinib binds 20-fold more tightly to the L858R mutant than to the wild-type enzyme.

DiseaseDisease

Known diseases associated with this structure: Adenocarcinoma of lung, response to tyrosine kinase inhibitor in OMIM:[131550], Nonsmall cell lung cancer, response to tyrosine kinase inhibitor in OMIM:[131550], Nonsmall cell lung cancer, susceptibility to OMIM:[131550]

About this StructureAbout this Structure

2ITQ is a Single protein structure of sequence from Homo sapiens with as ligand. Active as Receptor protein-tyrosine kinase, with EC number 2.7.10.1 Known structural/functional Site: . Full crystallographic information is available from OCA.

ReferenceReference

Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity., Yun CH, Boggon TJ, Li Y, Woo MS, Greulich H, Meyerson M, Eck MJ, Cancer Cell. 2007 Mar;11(3):217-27. PMID:17349580

Page seeded by OCA on Thu Feb 21 17:55:56 2008

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA